PRLD

Prelude Therapeutics Incorporated

$3.82 -2.55%

Recent alerts on PRLD

All signals →

News Prelude Cuts Q2 Losses and Costs 13%

Insider trade Purchase by BAKER JULIAN

Insider trade Purchase by BAKER FELIX

Insider trade Purchase by Baker Brothers Life Sciences LP

Insider trade Purchase by Baker Bros. Advisors (GP) LLC

Insider trade Purchase by 667, L.P.

Insider trade Purchase by BAKER BROS. ADVISORS LP

SEC filing PRLD Initiates PRT12396 Phase 1 Study, $90M Offering Extends Cash Runway into Q2 2028

Insider trade Purchase by David P Bonita

Insider trade Purchase by ORBIMED ADVISORS LLC / OrbiMed Capital GP VI LLC / ORBIMED CAPITAL LLC / OrbiMed Genesis GP LLC

Insider trade Purchase by ORBIMED ADVISORS LLC / OrbiMed Capital GP VI LLC / ORBIMED CAPITAL LLC / OrbiMed Genesis GP LLC

Insider trade Purchase by David P Bonita

News Prelude Therapeutics prices $90M equity offering

SEC filing PRLD Announces $25M Offering via Jefferies, $75M Shelf; Morgan Lewis Legal Opinion Filed

News Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

News Provident Dumps 490,000 MapleBear Shares Worth $18 Million

News What Makes Warrior Met Coal (HCC) an Attractive Stock?

News Prelude climbs as FDA clears study for Incyte-partnered cancer candidate

Scanner Unusual volume (z=4.9)

Get push alerts for PRLD

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS